palo-alto-biotech
(2)
Auransa
Auransa is a clinical-stage, AI-native biopharmaceutical company in Palo Alto, California, that uses a proprietary machine-learning platform - the SMarTR Engine - to mine large, heterogeneous human disease datasets and discover novel cancer therapies without starting from a predefined drug target. Founded in 2014 by Pek Lum and Viwat Visuthikraisee, the company pairs each predicted compound with the patient subtypes most likely to respond, aiming to improve the odds of clinical success. Its lead program, AU-409, an RNA transcription modulator for advanced liver cancer, is in Phase 1 trials, with additional programs including heart-safe chemotherapy.
Grace Science, LLC
Grace Science, LLC is a Palo Alto-based biotechnology company founded in 2017 by Silicon Valley entrepreneur Matt Wilsey and Nobel laureate chemist Dr. Carolyn Bertozzi to develop therapies built on the biology of NGLY1, an enzyme central to protein quality control. The company grew out of a father's search for a treatment after his daughter Grace was diagnosed with ultra-rare NGLY1 Deficiency. Its lead program, GS-100, is an AAV9 gene replacement therapy now in a Phase 1/2/3 clinical trial and holds FDA RMAT designation. Grace Science also pursues small-molecule and biomarker work that extends NGLY1 biology into oncology and neurodegeneration.